SCHEMBL12418599

SCHEMBL12418599

CC(C)(C)CCC(C)(C)Cl

nearest known ligand 0.36

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.36
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL740669 0.88 TSHR (0.46) TSHR
SCHEMBL19885950 0.79 TSHR (0.31) TSHR
SCHEMBL598853 0.78 TSHR (0.46) TSHRTDP1
SCHEMBL6983780 0.77 TSHR (0.36) TSHRTDP1
SCHEMBL11049364 0.77 TSHR (0.36) TSHR
SCHEMBL9808403 0.77 TSHR (0.36) TSHR
SCHEMBL4666436 0.72 TSHR (0.39) TSHR
SCHEMBL28713347 0.72 ALDH1A1 (0.67) TSHR
SCHEMBL10756606 0.69 TSHR (0.33) TSHRTDP1
SCHEMBL993354 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9394390-B2 Coumarin-functionalized polyolefin and associated cyclodimerization products, preparation methods, and electronic devices THE UNIVERSITY OF MASSACHUSETTS (US) 2016-07-19 US disclosed
US-20150361195-A1 COUMARIN-FUNCTIONALIZED POLYOLEFIN AND ASSOCIATED CYCLODIMERIZATION PRODUCTS, PREPARATION METHODS, AND ELECTRONIC DEVICES THE UNIVERSITY OF MASSACHUSETTS 2015-12-17 US disclosed
US-8765719-B2 Therapeutic drug for adult T-cell leukemia KAGOSHIMA UNIVERSITY (JP) 2014-07-01 US disclosed
US-20110172185-A1 THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA KAGOSHIMA UNIVERSITY (JP) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172185-A1 THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA CBR3, CD47, ATL3 TSHR 174/4885TDP1 2701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.